TNFRSF10B and neoplasm: Small EVs expressing DR5 agonist single‐chain variable fragment (ScFv) (DR5 sEVs) were engineered from CAR‐NK92 cells, as previously described.[27] NK‐92 cells, which naturally produce sEVs containing cytotoxic proteins with anti‐tumor activity, were genetically modified to secrete sEVs displaying DR5‐CAR agonistic scFvs on their surface.